Earnings Feed
Start Free
Bellerophon Therapeutics, Inc.·5

Jan 2, 1:39 PM ET

Linde North America, Inc. 5

5 · Bellerophon Therapeutics, Inc. · Filed Jan 2, 2018

Insider Transaction Report

Form 5Exit
Period: 2017-12-31
Bellerophon Therapeutics, Inc.BLPH
Linde North America, Inc.
10% Owner
Transactions
  • Purchase

    Common Stock

    [F1]
    2016-11-29+1,920,000→ 5,271,796 total
  • Purchase

    Common Stock

    [F2]
    2017-09-29+1,721,992→ 5,271,796 total
  • Purchase

    Common Stock Warrants (right to buy)

    [F1][F3]
    2016-11-29+1,920,000→ 1,920,000 total
    Exercise: $0.80Exp: 2021-11-29→ Common Stock (1,920,000 underlying)
  • Purchase

    Common Stock Warrants (right to buy)

    [F2][F4]
    2017-09-29+1,721,992→ 1,721,992 total
    Exercise: $1.24Exp: 2022-09-29→ Common Stock (1,721,992 underlying)
Footnotes (4)
  • [F1]The reported securities are included within Units purchased by the reporting person for $0.70 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock.
  • [F2]The reported securities are included within Units purchased by the reporting person for $1.205 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock.
  • [F3]The warrants to purchase shares of common stock are currently not exercisable by Linde North America, Inc. due to the exercise limitations of the warrants.
  • [F4]The warrants to purchase shares of common stock are currently not exercisable by Linde North America, Inc. due to the exercise limitations of the warrants.
Signature
/s/ Jens Luehring, Chief Executive Officer|2018-01-02

Documents

1 file
  • 5
    form5.xmlPrimary